BPC-157 vs TB-500: Mechanism, Cost, and Why They Are Combined

BPC-157 is a pentadecapeptide — fifteen amino acids, sequence GEPPPGKPADDAGLV — and a partial sequence of a larger protein originally isolated from human gastric juice and named Body Protection Compound. The literature calls it "stable gastric pentadecapeptide BPC 157" because laboratory work reported it remaining intact in gastric juice for hours rather than minutes, which is why it was first studied in the digestive tract. It is not a hormone, not a steroid and not a growth hormone secretagogue. The full reference is at what is BPC-157.

Four pathways recur across the animal and cell literature. All of the mechanistic detail is preclinical.

Angiogenesis through VEGFR2. A 2017 paper in the Journal of Molecular Medicine reported BPC-157 activating the VEGFR2 receptor and its downstream Akt–eNOS signaling in endothelial cells and in a rat model of limb ischemia, and a 2009 paper in the Journal of Physiology and Pharmacology described a modulatory effect on angiogenesis in healing rat muscle and tendon. Tendon and ligament are poorly vascularized, and blood supply is often the rate-limiting step.

Nitric oxide signaling. A 2014 review in Current Pharmaceutical Design summarized a long line of rat work describing BPC-157 interacting with the nitric oxide system, including counteracting the effects of NO-synthase blockade. This is closely tied to the vascular work rather than separate from it.

Growth hormone receptor upregulation in tendon fibroblasts. A 2014 paper in Molecules reported that BPC-157 increased growth hormone receptor expression in cultured rat tendon fibroblasts — a claim about how responsive those cells are to growth hormone already present, not a claim that growth hormone levels rise.

Cell survival and migration. A 2011 paper in the Journal of Applied Physiology described BPC-157 promoting tendon outgrowth, fibroblast survival under oxidative stress and fibroblast migration, with activation of the FAK–paxillin pathway that governs how cells attach and move into a wound.

Tendon. A 2003 paper in the Journal of Orthopaedic Research reported faster healing of a transected rat Achilles tendon and stimulated tendocyte growth in culture; a 2006 paper in the same journal examined Achilles detachment from bone in rats and reported accelerated reattachment and improved functional recovery.

Ligament. A 2010 paper in the Journal of Orthopaedic Research reported improved healing of a transected medial collateral ligament in rats, assessed by function and histology.

Muscle. A 2006 paper in the Journal of Orthopaedic Research reported functional recovery of a transected rat quadriceps, and a 2008 paper in Surgery Today reported the same in a rat crush-injury model, measured by walking and weight-bearing rather than subjective reports.

Gastrointestinal lining. The deepest literature and the original one. A 2011 review in Current Pharmaceutical Design and a 2018 review in the same journal cover protection of the gut lining against NSAID- and alcohol-induced damage, inflammatory bowel models and fistula healing in rats.

There are no randomized controlled trials of BPC-157 for tendon, ligament or muscle injury in humans. The only randomized human study the FDA identified when it reviewed BPC-157 in 2026 was a single 2005 meeting abstract: a multicenter, double-blind, placebo-controlled study in which 53 people with mild-to-moderate ulcerative colitis received a BPC-157 enema or placebo once daily for two weeks. The FDA judged the abstract too incomplete on endpoint definition, inclusion criteria and statistics to support efficacy or safety. Beyond that there is prescriber experience, which is real but is not trial evidence. The honest framing is "described in preclinical research and used clinically."

BPC-157 is supplied as a multi-dose vial and injected subcutaneously once daily at the volume printed on the medication; the directions on the BPC-157 product page are the only ones that apply, and the physician who reviews your intake sets them. Refills run every 28 days, one vial per fill. It is also available as a pre-filled pepti Pen cartridge. Some prescribers direct injection near the injured area; others do not, because the mechanisms described are systemic.

The animal literature describes a wide margin between effective doses and doses that cause problems, and the toxicology article the FDA reviewed reported no mutagenicity and no teratogenicity in pregnant rats. What is reported clinically is mostly local: redness, mild soreness and occasional bruising at the injection site, with some early nausea or light-headedness. The FDA's review lists injection-site reaction among the adverse-event reports in its database while noting it cannot attribute them to the peptide. There is no established interaction list because the trials that would produce one have not been run, which is why a physician reviews every medication on your intake. Is BPC-157 safe goes deeper.

TB-500 is a synthetic seven-amino-acid peptide, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, with an acetyl group on the N-terminal leucine. That sequence is the actin-binding domain of thymosin beta-4, a 43-amino-acid protein that is one of the most abundant proteins inside many human cells and is released into wound fluid and plasma after injury. A 2005 review in Trends in Molecular Medicine describes thymosin beta-4 as an actin-sequestering protein that "moonlights" in tissue repair, and a 2010 paper in the FASEB Journal mapped its biological activities onto short peptide sequences, including the actin-binding region that TB-500 reproduces.

The distinction matters when reading the research. Most of the thymosin beta-4 literature, including every human trial, used the full-length protein. That the fragment reproduces what the parent does is a reasonable assumption supported by cell and animal work on the actin-binding domain, but it is an assumption, and the FDA's 2026 review noted that it identified no in-vivo pharmacology studies of the fragment itself at the time of its evaluation. The full reference is at what is TB-500.

Actin is the protein that gives a cell its internal scaffold and lets it move. Thymosin beta-4 binds monomeric actin and regulates how much is available to polymerize, which is the basis of its described effect on cell migration. A 1997 paper in the FASEB Journal reported thymosin beta-4 stimulating directional migration of human endothelial cells, and a 2004 paper in Nature described it activating integrin-linked kinase and promoting cardiac cell migration and survival in mice. Repair cells physically moving into a wound is the job TB-500 is chosen for.

• Angiogenesis and wound closure. A 1999 paper in the Journal of Investigative Dermatology reported accelerated dermal wound healing in rats; a 2004 paper in Mechanisms of Ageing and Development described angiogenesis, wound healing and hair-follicle development.
• Matrix remodeling. A 2006 paper in the Journal of Cellular Physiology described increased matrix metalloproteinase expression during wound repair; a 2004 paper in Experimental Cell Research reported laminin-5 production in corneal cells.
• Inflammatory signaling. A 2007 paper in Experimental Eye Research and a 2011 paper in the FASEB Journal described suppression of NF-κB activation and IL-8 expression.
• The actin-binding fragment specifically. A 2003 paper in Wound Repair and Regeneration reported that a synthetic peptide containing the actin-binding domain, like the full protein, promoted dermal wound repair in diabetic and aged mice — the closest published bridge to the TB-500 sequence.

The thymosin beta-4 animal literature is concentrated in three tissues. Skin: the rat and mouse wound models above, summarized in a 2010 review in the Annals of the New York Academy of Sciences. Cornea: a 2002 paper in Experimental Eye Research reported faster corneal wound healing and less inflammation after alkali injury, and a 2002 paper in Current Eye Research reported conjunctival epithelial cell migration. Heart: a 2007 paper in Nature described mobilization of adult epicardial progenitor cells and neovascularization in mice, and a 2023 paper in Cardiovascular Research reported cardiac regeneration after ischemic injury in mice.

For tendon — the use most people have in mind — the first controlled animal study of TB-500 itself was published in July 2026 in Joint Diseases and Related Surgery. It is described below because it tested both peptides side by side.

For TB-500 the fragment, none. The FDA's review stated that it found no information in the medical literature where TB-500 was administered to patients for any condition, and described the absence of human data via any route as its particular concern.

For full-length thymosin beta-4 there is a small clinical program, and it should not be understated. A 2010 randomized, placebo-controlled single- and multiple-dose study in the Annals of the New York Academy of Sciences gave intravenous thymosin beta-4 to healthy volunteers and reported it well tolerated. A 2012 paper in the same journal reported phase 2 results in patients with chronic pressure ulcers and venous stasis ulcers. A 2015 phase 2 randomized trial in Cornea reported improved signs and symptoms of severe dry eye with thymosin beta-4 eye drops. These are trials of a different molecule, by a different route, for indications that are not tendon injury, and none is a large phase 3. They establish that the parent protein has been given to people under trial conditions; they do not establish what an injected fragment does for a sore Achilles.

TB-500 is supplied as a multi-dose vial for subcutaneous injection on the same daily rhythm as BPC-157, which is what makes a single combined vial workable. The directions on the TB-500 product page are the ones that apply; the physician sets the volume and it is printed on the medication. Refills run every 28 days, one vial per fill.

The clinical picture is similar to BPC-157: injection-site redness and tenderness, with occasional reports of tiredness in the first days. The FDA's review identified no nonclinical toxicity studies of the fragment and no human safety data, and its stated concern for any injected peptide is immunogenicity — the possibility that aggregates or synthesis impurities provoke an immune response — rather than any specific reported harm. That is an argument for sourcing from a licensed pharmacy whose preparation is tested, which is what /quality and the lab results exist to show. Is TB-500 safe goes deeper.

BPC-157 alone is the common single-agent prescription when the complaint is gastrointestinal. The compound was originally identified in gastric juice, and the separate research line on protection of the gastrointestinal lining is what drives that use; the FDA's 2026 review likewise noted that gastrointestinal uses are the most commonly cited. This is covered in peptides for gut health. It is also a reasonable single agent for a recent, acute, clearly vascular-limited injury where the physician wants one variable at a time.

TB-500 alone is less common, and is usually a decision driven by something in the patient's history rather than by the injury. If there is a reason to avoid one agent, the other may be used by itself. It is also the agent a physician may reach for when a soft-tissue problem has plateaued despite rest and adequate blood supply, where the working hypothesis is that repair cells are not arriving.

For tendon, ligament and muscle injury the BPC-157 + TB-500 stack is the default prescription, for the phase logic above. It is one injection on one schedule with one refill, and it is the preparation most prescriber experience with musculoskeletal injury is built on. GLOW and KLOW are the same two peptides with additions, not alternatives to them.

If collagen and skin quality matter alongside the injury, GLOW adds GHK-Cu, the copper peptide whose collagen-synthesis work in fibroblasts was reported in FEBS Letters in 1988 and reviewed in BioMed Research International in 2015. If a systemic inflammatory component is also in play, KLOW adds KPV, the anti-inflammatory tripeptide described in Gastroenterology in 2008.

Either alone on cost grounds is a legitimate conversation. Fifty dollars a month is fifty dollars a month, and if your physician thinks one component carries most of the value for your specific injury, say so rather than assuming the combined vial is compulsory.

A compounding pharmacy may use a bulk drug substance only if it is a component of an FDA-approved drug, has a USP monograph, or appears on the FDA's 503A bulks list. While nominated substances await evaluation, the FDA sorts them into interim categories: Category 1 (under evaluation; the FDA does not intend to act against compounders using them under stated conditions), Category 2 (significant safety concerns identified) and Category 3 (nominated without adequate support).

BPC-157 and TB-500 were both placed in Category 2 in 2023. As of the FDA's safety-risks page, current to 22 April 2026, neither appears in the active Category 2 table. Both now sit in a section headed "Bulk drug substances nominated but withdrawn," which the FDA describes as substances "previously in category 2 of the interim policies" whose nominations "were withdrawn by the nominators." The FDA's original notes remain on that page: for BPC-157, a possible immunogenicity risk for certain routes and limited safety information; for "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," a possible immunogenicity risk and no identified human exposure data. Neither peptide appears in Category 1, 2 or 3 of the current 503A category document, updated 14 May 2026.

New nominations for both were then taken to the FDA's Pharmacy Compounding Advisory Committee. On 23 July 2026 the committee discussed BPC-157 (free base and acetate; the use the FDA evaluated was ulcerative colitis), KPV, TB-500 (free base and acetate; the use evaluated was wound healing) and MOTS-c, and on 24 July it discussed DSIP, Semax and Epitalon, under docket FDA-2025-N-6895.

The FDA's briefing document proposed not adding BPC-157 to the 503A bulks list: the substance is not well characterized physicochemically, safety and immunogenicity information is lacking, the single ulcerative colitis abstract is insufficient to judge effectiveness, and approved treatments for ulcerative colitis exist. It also recorded the rat pharmacology it found — protection against colonic fistulas and hepatic and gastrointestinal lesions — while noting that the molecular targets have not been identified.

The FDA's briefing document likewise proposed not adding TB-500: lack of characterization data, no identified history of pharmacy compounding, no human data by any route, no nonclinical toxicity studies of the fragment, and approved wound therapies exist. It did identify pharmacokinetic studies showing that subcutaneous TB-500 reaches the circulation and is broken down into smaller peptides, one of which showed wound-healing activity in vitro.

The committee did not follow staff. On BPC-157 it voted 8–6 with one abstention to recommend adding both the free base and the acetate to the 503A bulks list. On TB-500 the committee also voted to recommend inclusion; the FDA had not posted summary minutes with the tally as of the meeting page's last update on 6 August 2026, and contemporaneous reporting described the votes as narrow.

An advisory committee vote is a recommendation. The FDA issues its own determination after weighing the vote, the docket and its scientific review, and as of September 2026 that determination is pending for both. So the accurate description today is: no longer in Category 2, recommended for the positive list by the advisory committee against the FDA's own staff proposal, awaiting final FDA action. Neither BPC-157 nor TB-500 is an FDA-approved drug, and compounded medications are never FDA approved as finished products; they are prepared by a licensed pharmacy against an individual prescription. That is different from being illegal. Are peptides FDA approved covers the distinction.